© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
June 9th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions
June 7th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
June 6th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.